Order Liporase (Hyaluronidase) 1500 U for Clinics

Liporase (Hyaluronidase) 1500 U is a professional-use hyaluronidase product used in aesthetic practices for hyaluronic acid filler correction and reversal workflows. Licensed clinics and healthcare professionals can order Liporase Hyaluronidase 1500 U for treatment-room stock when trained injectors, documentation, and emergency escalation procedures are already in place. The practical ordering decision usually centers on the 1500 U vial strength, reconstitution workflow, lot traceability, and fit with clinic protocols for elective correction or urgent filler-related complications.

Clinic Ordering, Price, and Stock Planning

Liporase (Hyaluronidase) 1500 U should be treated as a clinic supply for trained professionals, not a consumer self-use product. Practices can view current pricing during ordering and match the quantity purchased to their expected filler-correction workload, complication-kit needs, and expiry rotation. A clinic with frequent lip, tear trough, midface, or migration-correction appointments may plan stock differently from a practice that reserves hyaluronidase mainly for urgent response pathways.

Before adding the product to routine inventory, define how the practice will receive, log, store, reconstitute, and document each vial. Account review for professional-use supply may include business identity, healthcare credentials, billing details, and a compliant receiving address. Products are sourced through vetted distributors and verified supply channels for licensed clinics, with temperature-controlled handling when required and tracked US delivery.

Cost assessment should include more than the Liporase hyaluronidase price shown at checkout. Real clinic cost also includes training, diluent availability, sterile preparation supplies, emergency-kit maintenance, waste from expired stock, and time spent documenting lot numbers and outcomes. Standardizing the same strength and workflow across injectors can reduce errors when a correction or vascular-compromise protocol must be started quickly.

Clinics reviewing broader removal stock can browse the Dermal Filler Removal category, while teams standardizing brand-specific inventory may reference the Liporase brand collection.

What Liporase Hyaluronidase 1500 U Is Used For

Hyaluronidase is an enzyme that breaks down hyaluronic acid, a substance used in many temporary dermal fillers. In aesthetic medicine, Liporase 1500 U is generally used for correction of unwanted hyaluronic acid filler placement, persistent fullness, contour irregularity, asymmetry, migrated filler, or urgent response when a qualified injector suspects filler-related vascular compromise. It is valued because the clinical target is the hyaluronic acid filler rather than routine volume enhancement.

This enzyme is not a universal dermal filler dissolver. It is relevant to hyaluronic acid-based materials and should not be assumed to dissolve calcium hydroxylapatite, poly-L-lactic acid, silicone, or other non-HA products. Accurate filler identification protects the clinic from ineffective treatment, unnecessary tissue trauma, and poor documentation. Practices handling mixed filler portfolios may find the article on dermal filler removal approaches useful when building internal protocols.

Why it matters: The treatment plan changes when the original product is not a hyaluronic acid filler.

Use in urgent complication management should sit within a wider clinical pathway. Hyaluronidase does not replace assessment of perfusion, pain, skin color, vision symptoms, anatomy, and escalation needs. For non-emergency aesthetic correction, many clinics plan staged treatment so edema and early contour change do not lead to unnecessary additional dosing.

Form, Strength, and Pack Details

Liporase (Hyaluronidase) 1500 U is commonly presented as a lyophilized powder that requires reconstitution before use. The 1500 U vial strength is the key strength used in clinic planning, and professional listings commonly describe cartons of multiple vials, often 10 vials. Current packaging, diluent inclusion, label language, and carton contents should be matched to the product supplied at the time of ordering and to the clinic’s internal receiving log.

Packaging details matter most when the product is stored in an emergency kit. Similar-looking cartons, different label languages, or changes in vial count can slow preparation if staff are not trained on the exact presentation. Receiving staff should enter batch number, expiry, storage location, and quantity on arrival so first-expiry-first-out rotation is easy to follow.

Reconstitution and Professional Administration Workflow

Reconstitution should follow the current product instructions and the clinic’s written SOP. Specific volumes and injection amounts depend on the indication, treatment area, filler burden, urgency, and injector judgment, so generalized online mixing ratios should not replace local protocol or professional training. Aseptic technique, clear tray setup, and immediate syringe labeling reduce preventable errors during both planned correction and urgent response.

Before use, the injector should establish the original filler brand when possible, treatment date, anatomic site, symptom timing, and reason for reversal. Baseline photographs and notes on swelling, firmness, tenderness, blanching, vascular signs, and patient-reported symptoms help the team separate expected post-treatment change from progression. For lip-specific correction, the article on lip filler hyaluronidase workflow can support SOP development without replacing clinical judgment.

Quick tip: Prepare the treatment note template before reconstitution so lot, site, indication, and follow-up fields are not missed.

In routine aesthetic correction, staged use often provides a cleaner reassessment point than aggressive one-session removal. Edema may temporarily distort the result, particularly in lips and tear troughs. In suspected vascular compromise, the clinic should follow its emergency protocol immediately, including escalation steps for severe pain, skin color change, visual symptoms, or worsening tissue findings.

Storage, Handling, and Treatment-Room Logistics

Unopened vials should be stored according to the current label and the practice’s medicines or supply policy. Clinics typically keep cartons dry, protected from excessive heat, segregated by lot and expiry, and accessible only to authorized staff. If Liporase is stocked inside a complication kit, the kit should still include access controls, expiry checks, and a documented restocking process after any use.

Once reconstituted, handling becomes more time-sensitive and should follow the clinic’s written rules. The SOP should define who may prepare the solution, how the syringe or tray is labeled, whether any holding time is permitted, and when unused material is discarded. Separate stock for elective correction, urgent complications, and training can reduce confusion in high-pressure situations.

Compatibility planning also matters. The clinic should maintain the approved diluent required by its protocol, appropriate syringes and needles, antiseptic supplies, documentation forms, and emergency medicines. Teams updating procedural standards may also review dermal filler injection safety protocols to align reversal stock with prevention, recognition, and escalation procedures.

Safety, Contraindications, and Monitoring

Known hypersensitivity to hyaluronidase or any listed excipient is a key safety concern. Caution is also important when the filler identity is uncertain, when active infection or significant inflammation is present at the treatment site, or when swelling prevents reliable anatomic assessment. Because hyaluronidase increases tissue permeability, its effect may extend beyond the exact injection point, so conservative mapping and consent language are important near cosmetically sensitive areas.

Common short-term reactions may include redness, swelling, tenderness, bruising, itching, and temporary contour change. These findings can reflect the enzyme, the injection process, or inflammation around the original filler. Less common but more serious concerns include allergic reactions, significant unintended volume loss, prolonged inflammation, incomplete correction, and worsening symptoms that require escalation.

Monitoring depends on why the product was used. Planned correction usually requires observation for local reaction, reassessment of contour, and documentation of follow-up timing. Urgent pathways demand closer attention to pain, blanching, dusky discoloration, delayed capillary refill, skin breakdown, neurologic symptoms, or visual disturbance. Any progressive or severe finding should be handled under the clinic’s emergency protocol rather than routine aftercare.

Drug and procedure interactions should be considered when other injectable medicines or local anesthetics are used in the same field. Hyaluronidase can alter dispersion of nearby injected agents. Records should show sequence, site, product, lot, and rationale clearly enough for later clinical review.

How It Fits With Other Filler-Removal Choices

Liporase is most relevant when the original product is a hyaluronic acid filler and the clinic has a clear goal for correction. Observation, massage under clinician direction, staged review, or additional diagnostic assessment may be more appropriate when no urgent signs exist and the aesthetic issue is mild, early, or difficult to interpret because of swelling. For migrated filler, delayed nodules, or uncertain product history, a structured assessment helps determine whether hyaluronidase is suitable.

Clinics developing a removal pathway may use migrated filler recognition and next steps to support triage training. A broader clinical discussion of the enzyme is also available in Liporase for aesthetic filler correction. These materials should support internal education, not replace product instructions or emergency protocols.

When selecting inventory, compare label language, vial strength, vial count, excipients, storage requirements, reconstitution steps, staff familiarity, and traceability. A product with a smaller carton may suit low-volume practices, while larger packs may fit clinics that perform frequent HA filler treatments and keep several emergency kits stocked.

Related Professional-Use Alternatives

Alternatives should not be treated as automatically interchangeable, even when they belong to the same enzyme class. Substitution review should cover active ingredient, stated units, excipients, preparation instructions, stability language, pack size, and documentation burden. The supervising clinician or clinic governance lead should decide whether staff training and SOPs need updating before a substitute is used.

A clinic should also consider whether the original filler mix is mostly HA-based. If non-HA products are used frequently, reversal planning must include product identification and non-enzyme management routes. Keeping a current filler inventory map can speed decision-making when patients present after treatment at another clinic.

Documentation and Governance Checks

Strong documentation protects both patient safety and inventory control. For each use, the record should include indication, filler history, treatment site, baseline findings, consent, vial lot number, expiry, reconstitution details required by policy, injection mapping, immediate response, adverse findings, and follow-up plan. Emergency cases should also document escalation decisions and the time course of symptoms.

Staff training should cover when hyaluronidase is appropriate, when it is unlikely to work, how allergy risk is handled, and which symptoms trigger urgent medical escalation. Clinics should define who may authorize use, who may reconstitute the product, and who may administer it. A clear chain of responsibility is especially important in med spa or multi-provider settings.

Inventory audits should reconcile physical stock against ordering records and treatment notes. Expired or damaged vials should be removed according to clinic policy. If a pack presentation changes, update kit checklists and staff instructions before the product is placed into active use.

Authoritative Sources

For regulatory drug-safety context, consult FDA drug information resources.

For indexed clinical literature on hyaluronidase and dermal filler correction, consult PubMed biomedical literature database.

This content is for informational purposes only and is not a substitute for professional medical advice.